Novo Nordisk A/S (NVO )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol NVO
- Company Novo Nordisk A/S
- Price $85
- Changes Percentage -17.83
- Change -18.44
- Day Low $81.5
- Day High $86.53
- Year High $148.15
- Year Low $81.5
- Market Cap $459,471,515,400
- Price Avg 50 EMA (D) $109.93
- Price Avg 200 EMA (D) $126.5
- Exchange NYSE
- Volume 53,361,361
- Average Volume 5,321,766
- Open $82.72
- Previous Close $103.44
- EPS 2.98
- PE 28.52
- Earnings Announcement 2025-02-05 06:30:00
- Shares Outstanding $5,405,547,240
Company brief: NOVO NORDISK A/S (NVO )
- Healthcare
- Biotechnology
- Mr. Lars Fruergaard Jorgensen
- https://www.novonordisk.com
- DK
- N/A
- 04-30-1981
- US6701002056
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Gilead Sciences, Inc. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
NVO Corporation News
US FDA approves Novo Nordisk's bleeding disorder drug
reuters.com -- The U.S. Food and Drug Administration has approved Novo Nordisk's drug for the prevention or reduction of bleeding episodes in patients with a type of blood-related disorder called hemophilia A, the a...
Novo Nordisk: Why the stock of the Danish pharmaceutical giant is plunging
youtube.com -- Emily Field, Barclays head of European pharmaceutical research, joins CNBC's 'The Exchange' to discuss why Novo Nordisk shares are falling, the competition in the weight-loss drug space, and more....
Novo Nordisk stock price takes a tumble after the Wegovy maker's next-generation weight-loss drug underwhelms
fastcompany.com -- CagriSema, a drug that Novo Nordisk had hoped would become its next generation weight-loss aid, has failed to meet expectations in late-stage trials, sending shares of the pharmaceutical giant tumblin...
Novo Nordisk Stock Plummets: Bearish Signals Dominate After Drug Trial Miss
benzinga.com -- Novo Nordisk A/S NVO is seeing its stock spiral downwards, with shares plummeting 20% early Friday following the release of Phase 3 trial data....
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
reuters.com -- Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the highes...
Novo Nordisk shares plummet after weight-loss drug's disappointing trial results
nypost.com -- Investors and analysts had eagerly awaited this data as a test of Novo's case that it has a strong pipeline of drugs to follow Wegovy in the fiercely competitive anti-obesity market....
Earnings Growth & Price Strength Make Novo Nordisk (NVO) a Stock to Watch
zacks.com -- The Zacks Focus List offers investors a way to easily find top-rated stocks and build a winning investment portfolio. Here's why you should take advantage....
Novo Nordisk stock plunges on obesity shot trial results
youtube.com -- Novo Nordisk (NVO) is falling by over 20% in Friday's pre-market trading after its experimental weight-loss shot CagriSema was found to help recipients lose less weight than previously forecasted in i...
Novo Nordisk: CagriSema Underwhelms In REDEFINE-1 Trial
seekingalpha.com -- Shares of Novo Nordisk A/S are down after underwhelming REDEFINE-1 trial results. The results were positive, but underperformed company and market expectations (including my own). The trial's flexible...
Novo Nordisk Stock: A Rare Buying Opportunity
seekingalpha.com -- As I'm writing these lines, Novo Nordisk A/S stock is down about 16% on the pre-market session after the news came out that CagriSema delivered disappointing trial results. I think this selloff is a r...